Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.48 |
| ▸ | TET3 | O43151 | 2/20 | 0.48 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL28541911 | 0.97 | SMN1; SMN2 (0.79) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL27589356 | 0.93 | SMN1; SMN2 (0.71) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL9782806 | 0.92 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL98496 | 0.91 | — | — | |
| Malic Acid SCHEMBL31673494 | 0.91 | — | — | |
| Malic Acid SCHEMBL31673489 | 0.91 | — | — | |
| Malic Acid SCHEMBL29410671 | 0.91 | SMN1; SMN2 (1.00) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL856 | 0.91 | — | — | |
| Malic Acid SCHEMBL89131 | 0.91 | SMN1; SMN2 (1.00) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL256122 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210307732-A1 | PORTABLE DRUG TESTING APPARATUS, SYSTEM, AND METHOD | WINDSOR SECURITIES LLC | 2021-10-07 | — | — | US | claimed |
| EP-3836845-A1 | PORTABLE DRUG TESTING APPARATUS, SYSTEM, AND METHOD | Buzzkill Labs, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| WO-2020242132-A1 | ENTERIC TABLET CONTAINING DIMETHYL FUMARATE | 주식회사 큐라클 | 2020-12-03 | — | — | WO | claimed |
| WO-2020036891-A1 | PORTABLE DRUG TESTING APPARATUS, SYSTEM, AND METHOD | BUZZKILL LABS, INC. (US) | 2020-02-20 | — | — | WO | claimed |
| CN-104644603-A | Ezetimibe effervescent tablets and preparation method thereof | SHANDONG LUKANG RECORD PHARMACEUTICALS CO LTD | 2015-05-27 | — | — | CN | claimed |
| CN-102753156-B | Oral complex formulation comprising probiotic composition and 5-HT4 receptor agonist and method for preparing same | HANMI HOLDINGS Co.,Ltd. (KR) | 2014-10-08 | — | — | CN | claimed |
| CN-102753156-A | Oral complex formulation comprising probiotic composition and 5-HT4 receptor agonist and method for preparing same | HANMI HOLDINGS CO LTD | 2012-10-24 | — | — | CN | claimed |
| EP-2457580-A1 | Absorption enhancers for drug administration | The UAB Research Foundation (US) | 2012-05-30 | — | — | EP | claimed |
| CN-102232929-A | Voriconazole dried suspension and preparation method thereof | HANGZHOU SHARPLY PHARM R & D INSTIT CO LTD | 2011-11-09 | — | — | CN | claimed |
| EP-1789075-A4 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | UAB RESEARCH FOUNDATION (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1789075-A2 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | THE UAB RESEARCH FOUNDATION (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006025882-A2 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | THE UAB RESEARCH FOUNDATION (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060045868-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | claimed |
| US-20060045869-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | claimed |
| EP-0754452-B1 | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract | TANABE SEIYAKU CO (JP) | 2002-10-02 | — | — | EP | claimed |
| US-6309666-B1 | HARD CAPSULE CONTAINING ACIDIC SUBSTANCE TO CONTROL RELEASE, POLYMER FILM SOLUBLE AT LOW PH, ENTERIC COATING FILM | TANABE SEIYAKU CO., LTD. (JP) | 2001-10-30 | — | — | US | claimed |
| EP-0754452-A2 | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract | TANABE SEIYAKU CO., LTD. (JP) | 1997-01-22 | — | — | EP | claimed |
| US-11999718-B2 | Pyrazole derivatives | APTABIO THERAPEUTICS INC. (KR) | 2024-06-04 | — | — | US | disclosed |
| WO-1992012952-A1 | MALIC ACID DERIVATIVES AND COMPOSITIONS FOR THE TREATMENT OF PSORIASIS | DEXTER CHEMICAL CORPORATION (US) | 1992-08-06 | — | — | WO | disclosed |
| US-4623614-A | SILICON GRAFT POLYMER, ANTISTATIC AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999718-B2 | Pyrazole derivatives | CYP11B1, CYP11B2, CYP3A43 | SMN1; SMN2 3921/4885TET2 4784/4885TET3 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.